rs1600482909 — JPH2 Ser101Arg

Rare pathogenic missense variant in junctophilin-2 that disrupts T-tubule/sarcoplasmic reticulum coupling and impairs calcium-induced calcium release, causing hypertrophic cardiomyopathy

See your personal result for JPH2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

JPH2 Ser101Arg — When the Heart's Calcium Relay Station Breaks Down

Each heartbeat begins with an electrical signal that triggers a precisely timed calcium surge inside cardiomyocytes (heart muscle cells). This surge does not come from outside the cell — it is amplified from within by a process called calcium-induced calcium release11 calcium-induced calcium release
Depolarization of the T-tubule membrane opens L-type calcium channels (dihydropyridine receptors, DHPRs), admitting a small calcium trigger current. This trigger opens nearby ryanodine receptors (RyR2) on the sarcoplasmic reticulum, releasing a much larger calcium store into the cytoplasm, producing the contractile force, in which a small trigger calcium current from the cell surface opens large calcium reservoirs inside the sarcoplasmic reticulum (SR). The precision of this relay depends entirely on the physical proximity of the T-tubule membrane (where calcium enters the cell) and the SR membrane (where calcium is stored). The protein that holds these two membranes together is junctophilin-2, encoded by JPH2.

The JPH2 Ser101Arg variant — a serine-to-arginine substitution at position 101 — was identified in the landmark 2007 paper by Landstrom and colleagues22 landmark 2007 paper by Landstrom and colleagues
Landstrom AP et al., J Mol Cell Cardiol 42:1026–35, 2007 — the study that established HCM as the first human disease caused by JPH2 mutations; three novel variants (S101R, Y141H, S165F) were found in 3 of 388 unrelated HCM patients and were absent in 1,000 ethnically matched control alleles as one of the founding mutations establishing HCM as a disease of junctophilin-2. It is classified Pathogenic by ClinVar (RCV000023408) for Hypertrophic Cardiomyopathy 17 (HCM17, OMIM 613873), the JPH2-linked HCM subtype.

The Mechanism

JPH2 is a bi-anchored membrane protein: its N-terminal MORN (Membrane Occupation and Recognition Nexus) motifs33 MORN (Membrane Occupation and Recognition Nexus) motifs
Eight tandem MORN repeats form a flat phospholipid-binding surface that docks JPH2 to the T-tubule membrane — these repeats are the most evolutionarily conserved part of the junctophilin family and are found across muscle types in organisms from C. elegans to humans anchor it to the T-tubule plasma membrane, while its C-terminal transmembrane domain inserts into the SR membrane. By spanning the 12–15 nm junctional cleft44 junctional cleft
The nanometer-scale gap between the T-tubule and SR membranes where the calcium relay signal must cross; the DHPR (T-tubule) and RyR2 (SR) must be within this distance for efficient calcium-induced calcium release, JPH2 physically tethers the two membranes and positions RyR2 channels directly opposite L-type calcium channels (DHPRs).

The S101R substitution resides within the conserved MORN motif region. Replacing a small, uncharged serine with a bulky, positively charged arginine at this critical membrane-anchoring domain disrupts JPH2's ability to properly dock to the T-tubule and maintain the junctional cleft architecture. Landstrom et al. demonstrated that S101R causes protein reorganization and mislocalization within cardiomyocytes. The downstream consequence is impaired coupling between DHPRs and RyR2 — calcium-induced calcium release becomes inefficient and dysregulated, producing attenuated calcium transients (mean ΔF/F0 of 0.474 in S101R-expressing cells versus 0.933 in wild-type controls) and marked cardiomyocyte hyperplasia (cell area increased from 63.3 μm² to 78.1 μm²). The net effect is a cardiomyocyte that contracts weakly yet hypertrophies as a compensatory response — the cellular fingerprint of HCM.

The Evidence

Landstrom et al. (2007)55 Landstrom et al. (2007)
Landstrom AP et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J Mol Cell Cardiol 42:1026–35 screened the complete JPH2 coding region in 388 unrelated HCM patients and found three novel heterozygous mutations — S101R, Y141H, and S165F — each in one patient and absent from 1,000 ethnic-matched control alleles. For S101R specifically, immunocytochemistry showed protein mislocalization, live-cell confocal calcium imaging demonstrated 49% reduction in global calcium flux, and morphometric analysis confirmed cardiomyocyte hyperplasia. This paper established "HCM as the first human disease associated with genetic defects in JPH2."

An independent Japanese cohort Matsushita et al. (2007)66 Matsushita et al. (2007)
Matsushita Y et al. Mutation of junctophilin type 2 associated with hypertrophic cardiomyopathy. J Hum Genet 52:543–548 confirmed JPH2 as an HCM gene by identifying additional variants (G505S and R436C) in 195 Japanese HCM patients, with G505S showing statistical significance (4/296 HCM patients vs 0/472 controls, p=0.022).

Beavers et al. (2014)77 Beavers et al. (2014)
Beavers DL et al. Emerging roles of junctophilin-2 in the heart and implications for cardiac diseases. Cardiovasc Res 103:198–207 synthesized the mechanistic evidence: JPH2 maintains junctional membrane complex integrity; loss of JPH2 function disrupts calcium spark fidelity, promotes arrhythmogenic spontaneous SR calcium release, and triggers pathological hypertrophic remodeling. This review established that JPH2 dysfunction is relevant not only to familial HCM but also to acquired heart failure, where JPH2 protein levels decline with disease progression.

The functional importance of JPH2 was reinforced by Reynolds et al. (2016)88 Reynolds et al. (2016)
Reynolds JO et al. Junctophilin-2 gene therapy rescues heart failure by normalizing RyR2-mediated Ca²⁺ release. Int J Cardiol 225:371–380, demonstrating that AAV9 delivery of wild-type JPH2 to failing mouse hearts fully rescued T-tubule architecture, normalized calcium spark frequency, suppressed pathological SR calcium leak, and restored contractile function — directly validating that JPH2 loss of function is the disease driver, and not merely a secondary change.

S101R is absent from gnomAD population databases, consistent with its strong negative selective pressure as a pathogenic dominant variant.

Practical Actions

Identifying a JPH2 S101R carrier changes clinical management immediately and substantially. HCM is the most common cause of sudden cardiac death in athletes and individuals under 35, with exercise being the predominant trigger. For carriers, the priorities are: (1) confirm LV hypertrophy and outflow tract anatomy at baseline, (2) assess arrhythmia burden and calculate sudden death risk, (3) restrict high-intensity exertion until formally cleared, and (4) extend genetic testing to first-degree relatives. As an autosomal dominant condition, each biological child of a carrier has a 50% probability of inheriting S101R.

Unlike sarcomeric thin-filament mutations (TPM1, TNNT2), which primarily increase calcium sensitivity of the contractile apparatus, JPH2 mutations act upstream by reducing calcium release amplitude — a mechanistically distinct pathway to the same hypertrophic phenotype. This distinction does not currently change clinical management but may influence future targeted therapies.

Interactions

JPH2 Ser101Arg shares the HCM phenotype with sarcomeric gene variants across MYBPC3, MYH7, TPM1, and TNNT2 (related_snps above include several). Patients with JPH2 S101R who also carry a sarcomeric HCM variant ("double-positive" HCM) would be expected to have earlier onset and more severe hypertrophy based on analogous digenic HCM observations, though no published case series specifically documents JPH2 S101R digenic combinations.

Within JPH2 itself, the other Landstrom 2007 variants Y141H and S165F localize to the conserved linker-helix region immediately downstream of the MORN motifs and disrupt T-tubule/SR coupling through the same junctional membrane complex mechanism. Co-occurrence of two JPH2 mutations is not documented and would be extraordinarily rare given the individually ultra-low population frequency of each variant.

Genotype Interpretations

What each possible genotype means for this variant.

TT No S101R Variant Normal

No JPH2 Ser101Arg mutation — standard population risk from this variant

You carry two copies of the normal JPH2 allele at this position and do not have the S101R mutation. Your risk of hypertrophic cardiomyopathy from this specific variant is not elevated. Essentially the entire general population shares this result — S101R is absent from gnomAD population databases, detected in only one patient among 388 unrelated HCM probands in the founding study. Other HCM-causing genes (MYBPC3, MYH7, TNNT2, TPM1, and other JPH2 variants) are not captured by this result.

GT S101R Carrier High Risk

Carries one copy of JPH2 Ser101Arg — pathogenic for hypertrophic cardiomyopathy

The S101R substitution (rs1600482909; NM_020433.5:c.301A>C on the JPH2 coding strand, corresponding to plus-strand T→G at chr20:44186405 GRCh38) replaces the small, hydroxyl-bearing serine with a large, basic arginine residue at a position within the first MORN domain cluster of junctophilin-2. MORN repeats are the most phylogenetically conserved part of the junctophilin family and form the primary membrane-docking interface for T-tubule attachment.

Mechanistically, the positive charge and bulk of arginine at position 101 distorts MORN domain geometry, impairing JPH2's ability to bind the inner T-tubule leaflet. The consequence is mislocalization of the junctophilin-2 protein within cardiomyocytes and widening or dissolution of the junctional cleft — the 12–15 nm gap across which L-type calcium channels (DHPRs) must signal to ryanodine receptors (RyR2). With junctional coupling disrupted, calcium-induced calcium release is inefficient: live-cell confocal calcium imaging of S101R-expressing HL-1 cardiomyocytes showed mean ΔF/F0 of 0.474 versus 0.933 in wild-type controls — approximately half the normal calcium flux. The cardiomyocytes responded with marked hypertrophy (cell area 78.1 μm² versus 63.3 μm²), directly paralleling the clinical LV wall thickening that defines HCM.

Clinical features of JPH2-associated HCM include: - Asymmetric septal hypertrophy (LV wall thickness ≥15 mm by echo or MRI) - Diastolic dysfunction with preserved ejection fraction early in disease - Exertional dyspnea, chest pain, pre-syncope; often asymptomatic in young carriers on initial family screening - Arrhythmia risk: non-sustained ventricular tachycardia (NSVT), atrial fibrillation; risk of sudden cardiac death, highest during vigorous exercise - Unlike many sarcomeric HCM genes, JPH2 mutations may present with a less severe outflow tract gradient phenotype due to the upstream calcium-channel coupling mechanism

The ESC and ACC/AHA HCM guidelines apply to all genotype-positive HCM regardless of the specific gene. Risk stratification tools (ESC HCM Risk-SCD calculator, AHA/ACC criteria) determine ICD eligibility.

GG Homozygous S101R Homozygous

Carries two copies of JPH2 Ser101Arg — severe HCM risk, an undescribed genotype

You carry two copies of the JPH2 S101R mutation, one on each chromosome 20. This genotype has not been described in any published clinical case — S101R itself was found in only one patient among 388 HCM probands in the founding study, and homozygosity would require two carrier parents, both of whom would be affected with HCM. The expected consequence is at minimum as severe as heterozygous S101R-associated HCM; whether homozygosity produces a qualitatively worse phenotype is unknown. Clinical management should proceed identically to that for heterozygous carriers, with urgent referral to an HCM specialist center. All biological children will inherit at least one copy of S101R.